Projects per year
Objectives To describe the baseline characteristics of the patients randomised into the ALL-HEART study.
Methods The primary endpoint of the ALL-HEART study is the composite of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. Secondary outcomes include all-cause mortality, quality of life and cost-effectiveness of allopurinol. The study will end when 631 adjudicated primary outcomes have occurred.
Results 5938 patients from the UK have been randomised into the ALL-HEART study. The mean age at randomisation was 72.1±6.8 (SD) years. 75.2% of participants are male. 56.5% are former smokers and 9.4% current smokers. Mean systolic blood pressure was 133±18 mmHg and mean diastolic blood pressure 72±11 mmHg. Mean body mass index was 28.9±5.3 kg/m2. The average duration of ischaemic heart disease was 11.5±7.9 years. 47.4% of participants had a history of previous myocardial infarction, 64.2% a history of angina, 56.4% a history of coronary revascularisation and 69.3% had other evidence of ischaemic heart disease. 57.6% had a history of hypertension. 3.9% had a history of previous cerebrovascular accident, 7.6% of peripheral arterial disease, 21.8% of diabetes mellitus, 8.9% of chronic obstructive pulmonary disease and 5.2% of heart failure.
Conclusions This large ongoing trial will determine whether allopurinol improves major cardiovascular outcomes in patients with ischaemic heart disease.
|Number of pages||1|
|Journal||Annals of the Rheumatic Diseases|
|Issue number||suppl. 2|
|Publication status||Published - 12 Jun 2018|
FingerprintDive into the research topics of 'AB1029 Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART) study: baseline characteristics of the randomised patient population'. Together they form a unique fingerprint.
- 1 Active
Allopurinol and Cardiovascular Outcomes in Patients with Ischaemic Heart Disease (Joint with Robertson Centre for Biostatistics, University of Nottingham and University College London)
1/09/13 → 1/07/22